Synopsis
0
FDA Orange Book
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]CEP/COS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] EU WC
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]NDC API
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Europe
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Canada
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Australia
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Related Excipient Companies
EUROAPI
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Rochem International Inc
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Nanjing Well Pharmaceutical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Shanghai Minbiotech
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Actylis
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Corel Pharma Chem
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Finar
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Kerry
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Nanjing Bold Chemical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Parenteral
Topical
Solubilizers
Granulation
Co-Processed Excipients
Fillers, Diluents & Binders
Emulsifying Agents
Controlled & Modified Release
Direct Compression
Coating Systems & Additives
Taste Masking
API Stability Enhancers
Surfactant & Foaming Agents
Disintegrants & Superdisintegrants
Film Formers & Plasticizers
Digital Content
NEWS #PharmaBuzz
Global Sales Information
Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
11
PharmaCompass offers a list of Sodium Hyaluronate API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Sodium Hyaluronate manufacturer or Sodium Hyaluronate supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Sodium Hyaluronate manufacturer or Sodium Hyaluronate supplier.
PharmaCompass also assists you with knowing the Sodium Hyaluronate API Price utilized in the formulation of products. Sodium Hyaluronate API Price is not always fixed or binding as the Sodium Hyaluronate Price is obtained through a variety of data sources. The Sodium Hyaluronate Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A EUFLEXXA injection manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of EUFLEXXA injection, including repackagers and relabelers. The FDA regulates EUFLEXXA injection manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. EUFLEXXA injection API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of EUFLEXXA injection manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A EUFLEXXA injection supplier is an individual or a company that provides EUFLEXXA injection active pharmaceutical ingredient (API) or EUFLEXXA injection finished formulations upon request. The EUFLEXXA injection suppliers may include EUFLEXXA injection API manufacturers, exporters, distributors and traders.
click here to find a list of EUFLEXXA injection suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A EUFLEXXA injection DMF (Drug Master File) is a document detailing the whole manufacturing process of EUFLEXXA injection active pharmaceutical ingredient (API) in detail. Different forms of EUFLEXXA injection DMFs exist exist since differing nations have different regulations, such as EUFLEXXA injection USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A EUFLEXXA injection DMF submitted to regulatory agencies in the US is known as a USDMF. EUFLEXXA injection USDMF includes data on EUFLEXXA injection's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The EUFLEXXA injection USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of EUFLEXXA injection suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The EUFLEXXA injection Drug Master File in Japan (EUFLEXXA injection JDMF) empowers EUFLEXXA injection API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the EUFLEXXA injection JDMF during the approval evaluation for pharmaceutical products. At the time of EUFLEXXA injection JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of EUFLEXXA injection suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a EUFLEXXA injection Drug Master File in Korea (EUFLEXXA injection KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of EUFLEXXA injection. The MFDS reviews the EUFLEXXA injection KDMF as part of the drug registration process and uses the information provided in the EUFLEXXA injection KDMF to evaluate the safety and efficacy of the drug.
After submitting a EUFLEXXA injection KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their EUFLEXXA injection API can apply through the Korea Drug Master File (KDMF).
click here to find a list of EUFLEXXA injection suppliers with KDMF on PharmaCompass.
A EUFLEXXA injection CEP of the European Pharmacopoeia monograph is often referred to as a EUFLEXXA injection Certificate of Suitability (COS). The purpose of a EUFLEXXA injection CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of EUFLEXXA injection EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of EUFLEXXA injection to their clients by showing that a EUFLEXXA injection CEP has been issued for it. The manufacturer submits a EUFLEXXA injection CEP (COS) as part of the market authorization procedure, and it takes on the role of a EUFLEXXA injection CEP holder for the record. Additionally, the data presented in the EUFLEXXA injection CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the EUFLEXXA injection DMF.
A EUFLEXXA injection CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. EUFLEXXA injection CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of EUFLEXXA injection suppliers with CEP (COS) on PharmaCompass.
A EUFLEXXA injection written confirmation (EUFLEXXA injection WC) is an official document issued by a regulatory agency to a EUFLEXXA injection manufacturer, verifying that the manufacturing facility of a EUFLEXXA injection active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting EUFLEXXA injection APIs or EUFLEXXA injection finished pharmaceutical products to another nation, regulatory agencies frequently require a EUFLEXXA injection WC (written confirmation) as part of the regulatory process.
click here to find a list of EUFLEXXA injection suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing EUFLEXXA injection as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for EUFLEXXA injection API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture EUFLEXXA injection as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain EUFLEXXA injection and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a EUFLEXXA injection NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of EUFLEXXA injection suppliers with NDC on PharmaCompass.
EUFLEXXA injection Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of EUFLEXXA injection GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right EUFLEXXA injection GMP manufacturer or EUFLEXXA injection GMP API supplier for your needs.
A EUFLEXXA injection CoA (Certificate of Analysis) is a formal document that attests to EUFLEXXA injection's compliance with EUFLEXXA injection specifications and serves as a tool for batch-level quality control.
EUFLEXXA injection CoA mostly includes findings from lab analyses of a specific batch. For each EUFLEXXA injection CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
EUFLEXXA injection may be tested according to a variety of international standards, such as European Pharmacopoeia (EUFLEXXA injection EP), EUFLEXXA injection JP (Japanese Pharmacopeia) and the US Pharmacopoeia (EUFLEXXA injection USP).
